Le Lézard
Classified in: Health, Science and technology
Subject: FDA

FDA grants Oxehealth Vital Signs De Novo clearance


OXFORD, England, March 31, 2021 /PRNewswire/ -- Oxehealth has announced another world first after the US Food and Drug Administration granted a De Novo clearance for its Oxehealth Vital Signs product, which is incorporated into Oxevision, the vision-based patient monitoring and management platform delivered as software as a service.

Oxehealth Chief Executive Hugh Lloyd-Jukes said, "Receiving a de novo FDA clearance and creating an entirely new category of medical device is an exceptional achievement for Oxehealth. We are excited that we can now begin partnering with clinicians and the leadership teams of healthcare providers in America to enable them to deliver safer, higher quality and more cost-efficient care."

Oxehealth Chairman James Ede-Golightly said, "Oxevision has supported the provision of over 5 million hours of patient care. Approaching 40% of English Mental Health Trusts rely on Oxevision to support the work of their clinical teams. Our experience in the UK and Swedish markets positions us strongly for success in the US market."

About Oxehealth

Oxehealth is a vision-based patient monitoring and management company.  We help clinicians to deliver safer, higher quality and more cost-efficient care in inpatient and residential care settings.

Our Oxevision platform enables staff both to plan patient care and to intervene proactively to help patients.

Unlike conventional remote patient monitoring companies, Oxevision includes a contact-free optical sensor which detects patient vital signs and behaviour and delivers a secure on demand video feed.

Oxevision provides staff with a wider range of clinically validated early warning signs and risk factors than any competing technology, plus the ability to check the patient visually before choosing their intervention.

Our Oxehealth Service supports customers to deploy the Oxevision platform and to use it to create proactive, data-enabled systems of care that deliver not only a step change on deploying the system but also year on year continuous improvement in safety, quality and cost efficiency.

Patients benefit from improved care outcomes, better sleep and more privacy.

Staff have more time to care, greater peace of mind and the chance to use improved clinical insights to work "at the top of their band".

Oxehealth's website: www.oxehealth.com 
Learn more about Oxevision: www.oxehealth.com/oxevision 

Contact:
Ben Walsh
[email protected]
(+44)07554018066
Head of Marketing

SOURCE Oxehealth


These press releases may also interest you

at 00:25
Shanghai Junshi Biosciences Co., Ltd ("Junshi Biosciences," HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced its financial...

28 mar 2024
The report titled "Central Lab Market by Service Type (Anatomic Pathology/Histology, Biomarker Services, Genetic Services), Phase (Phase 1, Phase 2, Phase 3), Therapeutic Area, End-use - Global Forecast 2024-2030" is now available on...

28 mar 2024
The report titled "Personalized Nutrition Market by Measurement Type (Active Measurement, Standard Measurement), Application (Indication-based, Standard Supplements), Distribution Channel, End-Use - Global Forecast 2024-2030" is now available on...

28 mar 2024
The report titled "Carbon Dioxide Incubator Market by Product (Air Jacketed CO2 Incubators, Direct Heat CO2 Incubators, Water Jacketed CO2 Incubators), Capacity (100-200 Litre, Above 200 Litre, Below 100 Litre), Application, End User - Global...

28 mar 2024
The "Global Clinical In Vitro Diagnostic Medical Laboratory Services Market: Strategy & Trends with Volume & Price Forecasts by Chemistry, Hematology, Microbiology, Pathology, Covid-19, and Molecular Dx by Country. Updated with Impact of COVID-19"...

28 mar 2024
The "Molecular Diagnostics at the Point of Care. By Application, Technology, Place, Product and by Country. With Executive Guides and Customization 2023 - 2027 " report has been added to  ResearchAndMarkets.com's offering. Infectious disease Dx is...



News published on and distributed by: